You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status
|
|---|---|
| Published in |
Advances in Therapy, November 2009
|
| DOI | 10.1007/s12325-009-0072-z |
| Pubmed ID | |
| Authors |
Lance L. Stein, Mamie H. Dong, Rohit Loomba |
| Abstract |
Nonalcoholic fatty liver disease (NAFLD), first described in 1980, is now recognized as one of the most common causes of elevated liver enzymes and chronic liver disease in Western countries. The incidence of NAFLD in both adults and children is rising, in conjunction with the burgeoning epidemics of obesity and type 2 diabetes mellitus. NAFLD often coexists with other sequelae of the metabolic syndrome: central obesity, type 2 diabetes, hypertension, and hyperlipidemia. NAFLD encompasses a spectrum of pathologic liver diseases ranging from simple hepatic steatosis to a predominant lobular necro-inflammation, with or without centrilobular fibrosis (called nonalcoholic steatohepatitis or NASH). NASH can progress to cirrhosis, decompensated liver disease, and hepatocellular carcinoma. Though the natural history of NASH is still not clearly defined, it has been observed to progress to cirrhosis in 15%-220% of those affected. Insulin resistance is nearly universal in NASH and is thought to play an important role in its pathogenesis leading to dysregulated lipid metabolism. The prevalence of insulin resistance is reported in the general population to be approaching 45%, suggesting that NAFLD and NASH will contin nue to be an important public health concern. To date, NASH has proven to be a difficult disease to treat. Front-line therapy with lifestyle modifications resulting in weight loss through decreased caloric intake and moderate exercise is generally believed to be beneficial in patients with NASH, but is often difficult to maintain long term. Given that insulin resistance plays a dominant role in the pathogenesis, many studies have examined the use of insulin sensitizers: the biguanides (metformin), thiazolidinediones (pioglitazone, troglitazone, and rosiglitazone), glucagon-like peptide-1-receptor agonists, or incretins (exenatide)in NASH. This review will provide an overview of insulin resistance in NAFLD and provide a detailed summary on the clinical data regarding the use of insulin sensitizers in NASH. |
Mendeley readers
The data shown below were compiled from readership statistics for 134 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Brazil | 1 | <1% |
| South Africa | 1 | <1% |
| India | 1 | <1% |
| New Zealand | 1 | <1% |
| United States | 1 | <1% |
| Unknown | 129 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 23 | 17% |
| Researcher | 17 | 13% |
| Student > Ph. D. Student | 16 | 12% |
| Student > Bachelor | 16 | 12% |
| Other | 10 | 7% |
| Other | 21 | 16% |
| Unknown | 31 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 53 | 40% |
| Agricultural and Biological Sciences | 15 | 11% |
| Sports and Recreations | 8 | 6% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 3% |
| Nursing and Health Professions | 3 | 2% |
| Other | 14 | 10% |
| Unknown | 37 | 28% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2019.
All research outputs
#7,410,276
of 22,656,971 outputs
Outputs from Advances in Therapy
#693
of 2,328 outputs
Outputs of similar age
#28,328
of 78,974 outputs
Outputs of similar age from Advances in Therapy
#3
of 5 outputs
Altmetric has tracked 22,656,971 research outputs across all sources so far. This one is in the 44th percentile – i.e., 44% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,328 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.3. This one has gotten more attention than average, scoring higher than 64% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 78,974 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 5 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.